Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs

Petrillo, S.; D’Amico, J.; La Rosa, P.; Bertini, E.S.; Piemonte, F. Int. J. Mol. Sci. 2019, 20, 5211. Doi:10.3390/ijms20205211 (registering DOI)

Different redox drugs, joined by their ability to modulate the NRF2 pathway, elicit differential response profiles in FRDA fibroblasts. Using drugs aimed at preventing inflammation (SFN, NAC), lipid peroxidation (DMF, OMAV, and EPI-743), or redox imbalance (SFN), “multi-target” synergic therapies can be developed in FRDA, based on the patient’s clinical conditions and therapeutic needs.

argeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs